ALSP Community Update from Vigil Neuroscience

Trial update and Community Webinar

Vigil Neuroscience have shared a community update for ALSP community members.

It includes an update from IGNITE, Vigil’s Phase 2 clinical trial evaluating iluzanebart (VGL101), and details of their community webinar on Tuesday 12th December 5:00PM (GMT)/12:00PM (EST).

To read the update: Vigil Community Update Nov23


Alex - The Leukodystrophy Charity